[Cryotherapy percutaneous for renal tumors: Our center's beginning experience]

OBJECTIVE - To evaluate oncologic and functional outcomes after percutaneous cryoablation (PCA) for renal masses based on our single center experience.

PATIENTS AND METHODS  - We retrospectively identified 26 patients who underwent PCA for 28 tumors between November 2006 and June 2011.

Patient's demographics and baseline clinical characteristics, tumor features, perioperative information, and postoperative outcomes we rerecorded. A biopsy was performed systematically before each procedure. Control imaging was obtained at 1, 3, 6 and 12 months, and yearly thereafter. Oncological outcomes were determined by radiographic evidence of tumor recurrence, which was defined by contrast enhancement at the cryoablation site on control imaging at M3.

RESULTS - Patients had mean age of 70.1 years, mean Charlson comorbidity index (CCI) and body mass index) were 6 and 29kg/m(2) respectively. There were 11 kidney transplants, including 4 solitary. Mean tumor size was 29.5mm and was represented mainly by clear cell renal cell carcinomas (16/28), endophytic (17/28) and midkidney (14/28) (±9.8). Twenty-five cryoablations were performed percutaneously by two lumbotomy. Mean clearance preoperative MDRD was 66,1mL/min. Mean length of stay was 3.3 days (±2.2). Intraoperative complications consisted of 2 pneumothorax and 6 minor complications postoperative (Clavien≤2). There were no major complications. Mean follow-up was 27.5 months (±15.7), MDRD clearance distance was 61.9mL/min. Overall survival and disease-specific survival was 100%, while the recurrence-free survival was 78.6% (5 recurrences and 1 failure treatment).

CONCLUSIONS - The percutaneous cryoablation provides a safe and oncologically to extirpative surgery for renal masses in patients with significant medical comorbidities.

LEVEL OF EVIDENCE - 5.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2016 Mar 28 [Epub ahead of print]

F Lalloué, A Ruffion, P-J Valette, S Crouzet, X Martin, O Rouvière, P Paparel

Service d'urologie, université Claude-Bernard Lyon 1, CHU Lyon Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite, France. Service d'urologie, université Claude-Bernard Lyon 1, CHU Lyon Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite, France., Service d'urologie, université Claude-Bernard Lyon 1, CHU Lyon Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite, France., Service d'urologie et de transplantation, université Claude-Bernard Lyon 1, CHU Édouard-Herriot, 3, place d'Arsonval, 69003 Lyon, France., Service d'urologie et de transplantation, université Claude-Bernard Lyon 1, CHU Édouard-Herriot, 3, place d'Arsonval, 69003 Lyon, France., Service d'urologie et de transplantation, université Claude-Bernard Lyon 1, CHU Édouard-Herriot, 3, place d'Arsonval, 69003 Lyon, France., Service d'urologie, université Claude-Bernard Lyon 1, CHU Lyon Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite, France.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe